PepGen Inc
Change company Symbol lookup
Select an option...
PEPG PepGen Inc
KLXE KLX Energy Services Holdings Inc
RPRX Royalty Pharma PLC
NUE Nucor Corp
MORN Morningstar Inc
TOP TOP Financial Group Ltd
VEEV Veeva Systems Inc
ETY Eaton Vance Tax-Managed Diversified Equity Income Fund
FDX FedEx Corp
TARO Taro Pharmaceutical Industries Ltd

Health Care : Biotechnology |
Company profile

PepGen Inc. is a biopharmaceutical company. The Company is engaged in developing a transformative oligonucleotide delivery technology and pipeline of product candidates to treat neuromuscular and neurologic diseases. Its enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. The Company, through its EDO platform, is developing a pipeline of disease-modifying peptide-conjugated oligonucleotide candidates to treat a variety of degenerative neuromuscular diseases. Its lead product candidates include PGN-EDO51 and PGN-EDODM1. Its lead product candidate, PGN-EDO51, is an EDO peptide conjugated to a phosphorodiamidate morpholino oligomer (PMO) therapeutic cargo, which is developed for the treatment of duchenne muscular dystrophy (DMD) patients with mutations amenable to exon 51-skipping approach. It is also developing PGN-EDODM1, for the treatment of myotonic dystrophy type 1 (DM1).


Last Trade
-2.85 (-18.06%)
B/A Size

Market Hours

Closing Price
Day's Change
0.49 (3.20%)
Bid close
Ask close
B/A Size
Day's High
Day's Low

10-day average volume:

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.